ACADIA Ebit vs Total Other Income Expense Net Analysis

ACAD Stock

USD 15.20 0.34 2.19%

ACADIA Pharmaceuticals financial indicator trend analysis is way more than just evaluating ACADIA Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ACADIA Pharmaceuticals is a good investment. Please check the relationship between ACADIA Pharmaceuticals Ebit and its Total Other Income Expense Net accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

Ebit vs Total Other Income Expense Net

Ebit vs Total Other Income Expense Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ACADIA Pharmaceuticals Ebit account and Total Other Income Expense Net. At this time, the significance of the direction appears to have no relationship.

The correlation between ACADIA Pharmaceuticals' Ebit and Total Other Income Expense Net is 0.0. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of ACADIA Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ACADIA Pharmaceuticals' Ebit and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of ACADIA Pharmaceuticals are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Ebit i.e., ACADIA Pharmaceuticals' Ebit and Total Other Income Expense Net go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Ebit

Total Other Income Expense Net

Most indicators from ACADIA Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.51.

	2021	2022	2023	2024 (projected)
Gross Profit	465.0M	507.1M	680.7M	714.7M
Total Revenue	484.1M	517.2M	726.4M	762.8M

Gross Profit Total Revenue

ACADIA Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.69	0.86	-0.77	0.29	0.93	0.66	0.96	0.73	0.76	0.76	0.74	0.39	-0.91	0.75	0.88	0.74	0.85	0.87	0.93	0.8	0.87	0.74	0.99	0.69	0.93
Short Long Term Debt Total	0.69		0.35	-0.3	0.39	0.72	0.98	0.82	0.9	0.83	0.84	0.98	0.05	-0.86	0.83	0.58	0.94	0.51	0.36	0.74	0.26	0.84	0.99	0.6	0.95	0.74
Total Stockholder Equity	0.86	0.35		-0.81	0.24	0.78	0.31	0.75	0.3	0.34	0.34	0.44	0.51	-0.68	0.36	0.79	0.33	0.9	1.0	0.74	0.96	0.53	0.41	0.91	0.33	0.74
Net Debt	-0.77	-0.3	-0.81		-0.45	-0.65	-0.3	-0.64	-0.36	-0.41	-0.4	-0.39	-0.47	0.57	-0.37	-0.95	-0.36	-0.73	-0.82	-0.65	-0.64	-0.55	-0.38	-0.81	-0.24	-0.65
Other Assets	0.29	0.39	0.24	-0.45		0.1	0.41	0.25	0.31	0.19	0.2	0.47	-0.13	-0.27	0.18	0.52	0.29	0.41	0.25	0.08	0.04	0.31	0.44	0.27	0.21	0.08
Common Stock Shares Outstanding	0.93	0.72	0.78	-0.65	0.1		0.67	0.96	0.7	0.74	0.75	0.75	0.44	-0.93	0.76	0.78	0.74	0.76	0.79	0.99	0.74	0.83	0.75	0.92	0.73	0.99
Non Current Liabilities Total	0.66	0.98	0.31	-0.3	0.41	0.67		0.79	0.9	0.82	0.83	0.98	-0.04	-0.84	0.81	0.58	0.93	0.49	0.32	0.69	0.2	0.83	0.98	0.57	0.91	0.69
Other Stockholder Equity	0.96	0.82	0.75	-0.64	0.25	0.96	0.79		0.82	0.82	0.83	0.84	0.3	-0.99	0.84	0.81	0.84	0.83	0.76	0.96	0.69	0.92	0.85	0.92	0.8	0.96
Total Liab	0.73	0.9	0.3	-0.36	0.31	0.7	0.9	0.82		0.98	0.98	0.87	0.02	-0.85	0.94	0.61	0.99	0.47	0.33	0.75	0.22	0.94	0.91	0.63	0.9	0.75
Other Current Liab	0.76	0.83	0.34	-0.41	0.19	0.74	0.82	0.82	0.98		1.0	0.79	0.1	-0.85	0.95	0.63	0.96	0.46	0.36	0.81	0.27	0.95	0.84	0.67	0.86	0.81
Total Current Liabilities	0.76	0.84	0.34	-0.4	0.2	0.75	0.83	0.83	0.98	1.0		0.81	0.09	-0.85	0.96	0.63	0.97	0.47	0.36	0.81	0.28	0.95	0.86	0.67	0.87	0.81
Property Plant And Equipment Net	0.74	0.98	0.44	-0.39	0.47	0.75	0.98	0.84	0.87	0.79	0.81		0.06	-0.88	0.8	0.65	0.92	0.6	0.45	0.75	0.33	0.84	1.0	0.66	0.9	0.75
Current Deferred Revenue	0.39	0.05	0.51	-0.47	-0.13	0.44	-0.04	0.3	0.02	0.1	0.09	0.06		-0.24	0.11	0.41	0.05	0.25	0.52	0.4	0.51	0.1	0.05	0.44	0.11	0.4
Retained Earnings	-0.91	-0.86	-0.68	0.57	-0.27	-0.93	-0.84	-0.99	-0.85	-0.85	-0.85	-0.88	-0.24		-0.87	-0.76	-0.87	-0.8	-0.69	-0.93	-0.62	-0.93	-0.89	-0.87	-0.84	-0.93
Accounts Payable	0.75	0.83	0.36	-0.37	0.18	0.76	0.81	0.84	0.94	0.95	0.96	0.8	0.11	-0.87		0.59	0.93	0.48	0.39	0.8	0.32	0.9	0.84	0.67	0.85	0.8
Cash	0.88	0.58	0.79	-0.95	0.52	0.78	0.58	0.81	0.61	0.63	0.63	0.65	0.41	-0.76	0.59		0.61	0.78	0.8	0.79	0.62	0.75	0.65	0.88	0.5	0.79
Non Current Assets Total	0.74	0.94	0.33	-0.36	0.29	0.74	0.93	0.84	0.99	0.96	0.97	0.92	0.05	-0.87	0.93	0.61		0.48	0.35	0.78	0.25	0.94	0.95	0.65	0.93	0.78
Non Currrent Assets Other	0.85	0.51	0.9	-0.73	0.41	0.76	0.49	0.83	0.47	0.46	0.47	0.6	0.25	-0.8	0.48	0.78	0.48		0.89	0.73	0.82	0.69	0.57	0.88	0.45	0.73
Cash And Short Term Investments	0.87	0.36	1.0	-0.82	0.25	0.79	0.32	0.76	0.33	0.36	0.36	0.45	0.52	-0.69	0.39	0.8	0.35	0.89		0.75	0.95	0.55	0.42	0.92	0.35	0.75
Common Stock Total Equity	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.73	0.75		0.7	0.88	0.76	0.91	0.76	1.0
Short Term Investments	0.8	0.26	0.96	-0.64	0.04	0.74	0.2	0.69	0.22	0.27	0.28	0.33	0.51	-0.62	0.32	0.62	0.25	0.82	0.95	0.7		0.45	0.3	0.86	0.3	0.7
Other Current Assets	0.87	0.84	0.53	-0.55	0.31	0.83	0.83	0.92	0.94	0.95	0.95	0.84	0.1	-0.93	0.9	0.75	0.94	0.69	0.55	0.88	0.45		0.87	0.81	0.83	0.88
Property Plant And Equipment Gross	0.74	0.99	0.41	-0.38	0.44	0.75	0.98	0.85	0.91	0.84	0.86	1.0	0.05	-0.89	0.84	0.65	0.95	0.57	0.42	0.76	0.3	0.87		0.66	0.91	0.76
Total Current Assets	0.99	0.6	0.91	-0.81	0.27	0.92	0.57	0.92	0.63	0.67	0.67	0.66	0.44	-0.87	0.67	0.88	0.65	0.88	0.92	0.91	0.86	0.81	0.66		0.6	0.91
Short Term Debt	0.69	0.95	0.33	-0.24	0.21	0.73	0.91	0.8	0.9	0.86	0.87	0.9	0.11	-0.84	0.85	0.5	0.93	0.45	0.35	0.76	0.3	0.83	0.91	0.6		0.76
Common Stock	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.73	0.75	1.0	0.7	0.88	0.76	0.91	0.76

Click cells to compare fundamentals

ACADIA Pharmaceuticals Account Relationship Matchups

ACADIA Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Total Stockholder Equity	699.1M	627.0M	540.9M	400.4M	431.8M	232.8M
Net Debt	(183.3M)	(281.6M)	(91.3M)	(52.8M)	(131.5M)	(124.9M)
Other Assets	5.3M	54.7M	16.0M	11.1M	12.7M	7.9M
Common Stock Shares Outstanding	147.2M	157.3M	160.5M	161.7M	163.8M	172.0M
Liabilities And Stockholders Equity	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Non Current Liabilities Total	9.2M	49.6M	63.2M	61.8M	62.9M	66.1M
Other Stockholder Equity	2.4B	2.6B	2.7B	2.8B	2.9B	3.0B
Total Liab	84.0M	155.6M	159.2M	187.4M	317.2M	333.1M
Other Current Liab	64.2M	92.4M	80.9M	103.6M	225.7M	237.0M
Total Current Liabilities	74.8M	106.0M	96.1M	125.6M	254.3M	267.0M
Property Plant And Equipment Net	12.7M	56.4M	66.3M	61.6M	56.5M	59.3M
Retained Earnings	(1.7B)	(2.0B)	(2.2B)	(2.4B)	(2.4B)	(2.3B)
Accounts Payable	7.2M	8.5M	6.9M	12.7M	17.5M	18.4M
Cash	189.7M	326.0M	147.4M	114.8M	188.7M	198.1M
Non Current Assets Total	22.9M	65M	82.3M	79.9M	132.8M	139.5M
Non Currrent Assets Other	7.6M	7.4M	6.6M	5.3M	5.1M	2.6M
Cash And Short Term Investments	697.4M	632.0M	520.7M	416.8M	438.9M	269.3M
Short Term Investments	507.7M	305.9M	373.3M	302.0M	250.2M	185.1M
Other Current Assets	18.6M	25.7M	23.9M	21.4M	39.1M	41.0M
Property Plant And Equipment Gross	12.7M	56.4M	66.3M	61.6M	66.0M	69.3M
Total Current Assets	760.3M	717.6M	617.8M	507.9M	616.1M	646.9M
Accumulated Other Comprehensive Income	297K	36K	(192K)	(975K)	24K	25.2K
Property Plant Equipment	3.2M	9.2M	66.3M	61.6M	70.8M	74.4M
Other Liab	2.9M	5.2M	7.0M	9.1M	10.4M	11.0M
Net Tangible Assets	696.6M	625.9M	540.9M	400.4M	460.5M	403.1M
Retained Earnings Total Equity	(1.5B)	(1.7B)	(2.0B)	(2.2B)	(1.9B)	(1.8B)
Capital Surpluse	1.9B	2.4B	2.6B	2.7B	3.1B	1.6B
Inventory	6.3M	9.7M	7.9M	6.6M	35.8M	37.6M
Intangible Assets	4.1M	2.6M	1.1M	65.5M	75.3M	79.1M
Net Receivables	37.9M	50.3M	65.3M	63.1M	102.4M	107.5M
Non Current Liabilities Other	9.2M	49.6M	7.0M	9.1M	15.1M	12.7M
Net Invested Capital	699.1M	627.0M	540.9M	400.4M	431.8M	401.6M
Net Working Capital	685.4M	611.6M	521.8M	382.3M	361.9M	383.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
GM	General Motors
CRM	Salesforce

When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:

How To Invest In ACADIA

Details

Is ACADIA Stock a good investment?

Details

What is ACADIA Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for ACADIA Stock analysis

When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Revenue Per Share

4.949

Quarterly Revenue Growth

0.738

Return On Assets

(0)

Return On Equity

(0)

The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ACADIA Ebit vs Total Other Income Expense Net Analysis

Ebit vs Total Other Income Expense Net

Ebit vs Total Other Income Expense Net Correlation Analysis

Correlation Coefficient

Ebit

Total Other Income Expense Net

ACADIA Pharmaceuticals fundamental ratios Correlations

ACADIA Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ACADIA Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for ACADIA Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Liabilities	+ 1.0	Other Current Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total

Retained Earnings	- 0.99	Other Stockholder Equity
Cash	- 0.95	Net Debt
Common Stock	- 0.93	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Common Stock Shares Outstanding